T3 Technion Technology Transfer

T3 Technion Technology Transfer is the commercialization arm of the Technion, Israel’s flagship engineering and applied-science university and the source of an unusually high concentration of robotic-surgery, medical-imaging, and deep-tech biology spinouts. For physician-scientist or engineer founders with Technion roots, T3 is the institutional starting point for turning research into a company.

The thesis is rooted in the Technion’s engineering and applied-science strengths. T3 commercializes biotech innovations, medical-device technologies, and AI-driven healthcare applications that emerge from Technion laboratories, with a particular reputation for hardware-heavy and computationally intensive companies. Robotic surgery, advanced imaging, and bio-engineering are categories where Technion spinouts have historically been most successful, and T3’s operating model reflects that. The fund does not publish a granular portfolio breakdown, but the spinout pattern is widely known in the Israeli ecosystem.

Check sizes sit below 250 thousand dollars, consistent with the pre-seed positioning and the academic-spinout model. Stage focus is firmly at the start: pre-seed and seed, with follow-on capital expected from Israeli deep-tech VCs, life-sciences specialists, and corporate strategics once the company has matured. Geography is Israel-anchored, with the expectation that companies will engage United States and European commercial markets as they scale.

The team is small and embedded in the Technion’s research and clinical-collaboration structures, with deep institutional knowledge of the university’s intellectual-property base. Diligence is built around the academic context and the strength of the underlying technology.

Approach T3 when you are a Technion researcher, clinician, or graduate with a research-derived invention and a willingness to spin out a company. Pure outside-the-university founders will not be a fit; T3’s role is to commercialize Technion intellectual property. The most direct path in is through your department, your principal investigator, or the T3 office directly. Time the conversation when you have a research insight with commercial potential, ideally with a working prototype and the institutional support to spin out. Founders should plan for a structured commercialization process and a long-term partnership with the university. T3 is particularly useful for founders building hardware-heavy or computationally intensive products where the Technion’s technical depth is the actual moat.